The recent successes of large, multicenter clinical trials of acetylcholinesterase inhibitors for symptomatic treatment of Alzheimer's disease have spawned enthusiasm that this common and fatal neurologic disease is “treatable.” A parallel explosion has occurred in the consumption of alternative medicines by the public seeking more effective, natural, or safer methods for treatment of dementia. Some of these medicines may, in fact, be biologically active in modulating the disease as well as producing side effects and interactions with accepted pharmaceuticals. This review brings to focus the scientific evidence presently available regarding such agents.
Get full access to this article
View all access options for this article.
References
1.
SmallGWRabinsPVBarryPBDiagnosis and treatment of Alzheimer disease and related disorders. JAMA1997; 278: 13631371
2.
American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry1997; 154(suppl):139
3.
ColemanLMFowlerLLWilliamsME. Use of unproven therapies by people with Alzheimer's disease. J Am Geriatr Soc1995; 43: 747750
4.
HoganDBEblyEM. Complementary medicine use in a dementia clinic population. Alz Dis Assoc Disord1996; 10: 6367
LogroscinoGMarderKCoteLDietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann Neurol1996; 39: 8994
7.
SmithMAPetotGJPerryG. Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease. Alz Dis Rev1997; 2: 5860
8.
KalmijnSFeskensEJMLaunerLJKromhoutD. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol1997; 145: 3341
9.
GravesABvan DuijnMCentraVAlcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. Int J Epidemiol1991; 20(suppl 2):S48-S57
10.
OrgogozoJMDartiguesJFLafontSWine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol1997; 153: 185192
11.
ConstantJ. Alcohol, ischemic heart disease, and the French paradox. Coron Artery Dis1997; 8: 645649
12.
KlatskyALArmstrongMAFriedmanGD. Red wine, white wine, liquor, beer, and risk for coronary artery disease hospitalization. Am J Cardiol1997; 80: 416420
13.
DayAPKempHJBoltonCHartogMStansbieD. Effect of concentrated red grape juice consumption on serum antioxidant capacity and low-density lipoprotein oxidation. Ann Nutr Metab1997; 41: 353357
14.
SoleasGJDiamandisEPGoldbergDM. Resveratrol: a molecule whose time has come? And gone?Clin Biochem1997; 30: 91113
15.
GehmBDMcAndrewsJMChienPYJamesonJL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A1997; 94: 1413814143
16.
GazianoJMBurningJEBreslowJLModerate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med1993; 329: 18291834
17.
StampferMJColditzGAWillettWCA prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med1988; 319: 267273
18.
GillJSZezulkaAVShipleyMJStroke and alcohol consumption. N Engl J Med1986; 315: 10411046
19.
ObisesanTOHirschRKosokoOModerate wine consumption is associated with decreased odds of developing age-related macular degeneration in NHANE-1. J Am Geriatr Soc1998; 46: 17
20.
MilesTP. Should my mother take a drink?J Am Geriatr Soc1998; 46: 114
21.
GibsonGESheuKFRBlassJPReduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol1988; 45: 836840
22.
EderLHirtLDunantY. Possible involvement of thiamine in acetylcholine release. Nature1976; 264: 186188
23.
EderLDunantY. Thiamine and cholinergic transmission in the electric organ of torpedo. J Neurochem1980; 35: 12781296
24.
MeadorKJNicholsMEFrankePEvidence for a central cholinergic effect of high-dose thiamine. Ann Neurol1993; 34: 724726
25.
BlassJPGleasonPBrushDThiamine and Alzheimer's disease: a pilot study. Arch Neurol1988; 45: 833835
26.
NolanKABlackRSSheuKFRA trial of thiamine in Alzheimer's disease. Arch Neurol1991; 48: 8183
27.
MeadorKLoringDNicholsMPreliminary findings of high-dose thiamine in dementia of Alzheimer's type. J Geriatr Psychiatry Neurol1993; 6: 222229
28.
AllenLHCasterlineJ. Vitamin B-12 deficiency in elderly individuals: diagnosis and requirements. Am J Clin Nutr1994; 60: 1214
29.
KristensenMOGulmannNCChristensenJEJSerum cobalamin and methylmalonic acid in Alzheimer type dementia. Acta Neurol Scand1993; 87: 475481
30.
BasunHFratiglioniLWinbladB. Cobalamin levels are not reduced in Alzheimer's disease: results from a population-based study. J Am Geriatr Soc1994; 42: 132136
31.
CrystalHAOrotofEFrishmanWHSerum vitamin B-12 levels and incidence of dementia in a healthy elderly population: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc1994; 42: 933936
32.
O'NeillDBarberRD. Reversible dementia caused by vitamin B-12 deficiency. J Am Geriatr Soc1993; 41: 192193
33.
MeadowsMEKaplanRFBromfieldEB. Cognitive recovery with vitamin B12 therapy: a longitudinal neuropsychological assessment. Neurology1994; 44: 17641765
34.
ChatterjeeAYapundichRPalmerCALeukoencephalopathy associated with cobalamin deficiency. Neurology1996; 46: 832834
35.
StojsavljevicNLevicZDrulovicJDragutinovicG. A 44-month clinical-brain MRI follow-up in a patient with B12 deficiency. Neurology1997; 49: 878881
36.
LindenbaumJHealtonEBSavageDGNeuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med1988; 318: 17201728
37.
MartinDCFrancisJProtetchJHuffFJ. Time dependency of cognitive recovery with cobalamin replacement: report of a pilot study. J Am Geriatr Soc1992; 40: 168172
38.
HughesDElwoodPCShintonNKWrightonRJ. Clinical trial of the effect of vitamin B12 in elderly subjects with low serum B12 levels. Br Med J1970; 2: 458460
39.
TeuniseSBollenAEvan GoolWAWalstraGJ. Dementia and subnormal levels of vitamin B12: effects of replacement therapy on dementia. J Neurol1996; 243: 522529
40.
IkedaTYamamotoKTakahashiKTreatment of Alzheimer-type dementia with intravenous mecobalamin. Clin Ther1992; 14: 426437
41.
PerrigWJPerrigPStahelinHB. The relation between antioxidants and memory in the old and very old. J Am Geriatr Soc1997; 45: 718724
42.
ChenCLMullerDCAndresRA prospective study of plasma levels of alpha-tocopherol (vitamin E), beta-carotene, and ascorbic acid (vitamin C) and risk of developing Alzheimer's disease in the Baltimore Longitudinal Study of Aging. Neurology1998; 50(suppl): A231–A232
43.
SanoMErnestoCThomasRGA controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med1997; 336: 12161222
44.
DrachmanDALeberP. Treatment of Alzheimer's disease—searching for a breakthrough, settling for less. N Engl J Med1997; 336: 12451247
45.
The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med1993; 328:176183
46.
ThalLJCartaAClarkeWRA 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology1996; 47: 705711
47.
SpagnoliALuccaUMenasceGLong-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology1991; 41: 17261732
48.
SanoMBellKCoteLDouble-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol1992; 49: 11371141
49.
RaiGWrightGScottLDouble-blind, placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin1990; 11: 638647
50.
LivingstonGASaxKBMcClenahanZAcetyl-L-carnitine in dementia. Int J Geriatr Psychiatry1991; 6: 853860
51.
PettegrewJHKlunkWEPanchalingamKClinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging1995; 16: 14
52.
PatelSH. Pharmacotherapy of cognitive impairment in Alzheimer's disease: a review. J Geriatr Psychiatry Neurol1995; 8: 8195
53.
ThalLJRosenWSharplessNSCholine chloride fails to improve cognition in Alzheimer's disease. Neurobiol Aging1981; 2: 205208
54.
EtiennePGauthierSJohnsonGClinical effects of choline in Alzheimer's disease. Lancet1978; 1: 500509
55.
CanterNLHallettMGrowdonJH. Lecithin does not affect EEG spectral analysis or P300 in Alzheimer's disease. Neurology1982; 32: 12601266
56.
PomaraNDominoEFYoonHFailure of single-dose lecithin to alter aspects of central cholinergic activity in Alzheimer's disease. J Clin Psychiatry1983; 44: 293295
57.
LittleALevyRChuaqui-KiddCA double-blind, placebo-controlled trial of high dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry1985; 48: 736742
58.
EtiennePDastoorDGauthierSAlzheimer's disease: lack of effect of lecithin treatment for 3 months. Neurology1981; 31: 15521554
59.
GauthierSBouchardRLamontagneATetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N Engl J Med1990; 322: 12721276
60.
ChatellierGLacomblezL. Tacrine and lecithin in senile dementia of the Alzheimer type: a multicenter trial. Br Med J1990; 300: 495499
61.
FittenLJPerrymanKMGrossPLTreatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry1990; 147: 239242
62.
EaggerSALevyRSahakianBJ. Tacrine in Alzheimer's disease. Lancet1991; 337: 989992
63.
MarshGRLinnoilaM. The effects of deanol on cognitive performance and electrophysiology in elderly humans. Psychopharmacology1979; 66: 99104
64.
FismanMMerskyHHelmesE. Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease. Am J Psychiatry1981; 138: 970972
65.
FerrisSHSathananthanGGershonSClarkC. Senile dementia: treatment with deanol. J Am Geriatr Soc1977; 25: 241244
66.
RoyDPathakDNSinghR. Effect of centrophenoxine on the antioxidative enzymes in various regions of the aging rat brain. Exp Gerontol1983; 18: 185197
67.
PekGFulopTZs-NagyI. Gerontopsychological studies using NAI on patients with organic psychosyndrome (DSMIII, Category 1) treated with centrophenoxine in a double blind, comparative, randomized clinical trial. Arch Gerontol Geriatr1989; 9: 1730
68.
AmaducciLSmidGroup. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull1988; 24: 130134
69.
CrookTHTinklenbergJYesavageJEffects of phosphatidylserine in age-associated memory impairment. Neurology1991; 41: 644649
70.
CrookTPetrieWWellsCMassariDC. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull1992; 28: 6166
71.
EngelRRSatzgerWGuntherWDouble-blind crossover study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol1992; 2: 149155
72.
HeissWDKesslerJMielkeRLong-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease: a neuropsychological, EEG, and PET investigation. Dementia1994; 5: 8898
73.
BeyerRE. An analysis of the role of coenzyme Q in free radical generation and as an antioxidant. Biochem Cell Biol1992; 70: 390403
LonnrotKMetsa-KetelaTAlhoH. The role of coenzyme Q-10 in aging: a follow-up study on life-long oral supplementation of Q-10 in rats. Gerontology1995; 41(suppl 2):109120
76.
MullerJLClausonKA. Pharmaceutical considerations of common herbal medicine. Am J Man Care1997; 3: 17531770
77.
TylerVE. The honest herbal—a sensible guide to the use of herbs and related remedies. 3rd Ed.New York: Pharmaceutical Products Press, 1993
ItilTMartoranoD. Natural substances in psychiatry (Ginkgo biloba in dementia). Psychopharmacol Bull1995; 31: 147158
80.
LeBarsPLKatzMMBermanNA placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. JAMA1997; 278: 13271332
81.
KnappMJKnopmanDSSolomonPRA 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA1994; 27: 985991
82.
RogersSLFarlowMRDoodyRSA 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology1998; 50: 136145
83.
MaurerKIhlRDierksTFrolichL. Clinical efficacy of Ginkgo Biloba extract Egb 761 in dementia of the Alzheimer type. J Psychiatr Res1997; 31: 645655
84.
ZhaoXZ. Antisenility effect of ginseng-rhizome saponin. Chung Hsi Chieh Ho Tsa Chih1990; 10: 586589
85.
SalimKNMcEwenBSChaoHM. Ginsenoside Rb1 regulates ChAT, NGF and trkA mRNA expression in the rat brain. Brain Res Mol Brain Res1997; 47: 177182
86.
BenishinCGLeeRWangLCLiuHJ. Effects of ginsenoside Rb1 on central cholinergic metabolism. Pharmacology1991; 42: 223229
87.
ChongSKFOberholzerVG. Ginseng—is there a use in clinical medicine?Postgrad Med1988; 64: 841846
88.
SiegelRK. Ginseng abuse syndrome. Problems with the panacea. JAMA1979; 241: 16141615
89.
ThommessenBLaakeK. Ginseng—no identifiable effect in geriatric rehabilitation. Tidsskr Nor Laegeforen1997; 117: 38393841
90.
SkolnickAA. Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy. JAMA1997; 277: 776
91.
XuSSGaoZXWengZEfficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Chung Kuo Yao Li Hsueh Pao1995; 16: 391395
92.
ZhangRWTangXCHanYYDrug evaluation of huperzine A in the treatment of senile memory disorders. Chung Kuo Yao Li Hsueh Pao1991; 12: 250252
93.
BaulieuEE. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res1997; 52: 132
94.
SchumacherMRobelPBaulieuEE. Development and regeneration of the nervous system: a role for neurosteroids. Dev Neurosci1996; 18: 621
95.
ValleeMMayoWDarnauderyMNeurosteroids: deficient cognitive performance in aged rats depends on low pregnenolone sulfate levels in the hippocampus. Proc Natl Acad Sci U S A1997; 94: 1486514870
96.
WatsonRRHulsAAraghinikuamMChungS. Dehydroepiandrosterone and diseases of aging. Drugs Aging1996; 9: 274291
97.
DanenboergHDHaringRFisherADehydroepiandrosterone increases production and release of Alzheimer's amyloid precursor protein. Life Sci1996; 59: 16511657
98.
MajewskaMD. Neuronal actions of DHEAS: possible roles in brain development, aging, memory, and affect. Ann N Y Acad Sci1995; 774: 111121
SunderlandTMerrilCRHarringtonMGReduced plasma dehydroepiandrosterone concentrations in Alzheimer's disease. Lancet1989; 2: 570
101.
NasmanBOlssonTBackstromTSerum dehydroepiandrosterone sulfate in Alzheimer's disease and in multi-infarct dementia. Biol Psychol1991; 30: 684690
102.
LegrainSBerrCFrenoyNDehydroepiandrosterone sulfate in a long-term care aged population. Gerontology1995; 41: 343351
103.
Spath-SchwalbeEDodtCDittmannJDehydroepiandrosterone sulfate in Alzheimer's disease. Lancet1990; 1: 1412
104.
LeblhuberFWindhagerEReiseckerFDehydroepiandrosterone sulfate serum levels in normal aging and Alzheimer's disease. Age1991; 14: 116118
105.
SchneiderLSHinseyMLynessS. Plasma dehydroepiandrosterone in Alzheimer's disease. Biol Psychol1922; 31: 205208
106.
WolfOTNeumannOHellhammerDHEffects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab1997; 82: 23632367
107.
BrzezinskiA. Melatonin in humans. N Engl J Med1997; 336: 186195
108.
DelagrangePGuardiola-LemaitreB. Melatonin, its receptors, and relationships with biological rhythm disorders. Clin Neuropharmacol1977; 6: 482510
109.
PenevPZeePC. Melatonin: a clinical perspective. Ann Neurol1997; 42: 545553
110.
PrinzPVitielloMVRaskindMAThorpyMJ. Geriatrics: sleep disorders and aging. N Engl J Med1990; 323: 520526
111.
PappollaMASosMOmarRAMelatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci1997; 17: 16831690
112.
PappollaMABoznerPSotoCInhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem1998; 273: 71857188
113.
SongWLahiriDK. Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendocrine cell line PC12. J Mol Neurosci1997; 9: 7592
114.
MelatoninMed Lett1995; 37:111112
115.
MishimaKOkawaMHishikawaYMorning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psych Scand1994; 89: 17
116.
SatlinAVolicerLRossVBright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease. Am J Psychiatry1992; 149: 10281032
117.
EisenbergDM. Advising patients who seek alternative medical therapies. Ann Intern Med1997; 127: 6169
